

Pakistan Automobile Sales

PV sales grow 46% in 8MCY26


Tuesday, September 15, 2026

Based on figures released by PAMA, Pakistan's passenger vehicle (PV) sales grew by 36% YoY to 13,717 units during August 2026. The SUV/Pickup segment fell 57% YoY to 1,730 units, dragged down by the effect of unavailable figures of Haval sales. Cumulatively, PV sales grew by 46% YoY to 120.7k units in 8MCY26, supported by lower interest rates, new model launches, and recovering economic activity.

Key Highlights


- Within the PV segment, Alto led the market with a share of 39% (5,339 units). It was followed by Corolla/Yaris (Share: 22%), Civic/City (Share: 19%), and Swift (Share: 11%).
- Improving economic conditions also support automobile sales via rising automobile financing. As of July 2026, the outstanding stock of **automobile financing grew by 35% YoY to PkR 386bn.**
- Monthly, the passenger vehicle (PV) segment recorded a fall of 20% MoM, easing back after a stronger July. Elevated interest rates and affordability pressures may have also weighed on sales during the period.

PV Market Share (August 2026)




Source: PAMA, BMA Research

PV Trend – Month of March



Source: PAMA, BMA Research

SUV Market Share (August 2026)



Source: PAMA, BMA Research

- The SUV / Pickup segment was led by Fortuner/Hilux with a share of 55% (950 units) during August 2026, followed by BR-V (share: 5%) and Tucson (share: negligible), as Haval volume is awaited and Tucson volumes fell to near zero YoY.


BMA Research

E-mail: research@bmacapital.com

BMA Capital Management Ltd.

- Tractor sales rose 6% YoY to 1,052 units in August 2026, down 15% MoM after a stronger July. Cumulatively, sales grew 30% YoY to 18,023 units in 8MCY26 on improving farm economics and a low base.
- Truck sales rose 35% YoY to 802 units in August 2026, with an even stronger 56% YoY cumulative gain to 6,024 units in 8MCY26. Isuzu led the segment with a 62% market share.
- The 2/3-wheeler segment grew 20% YoY to 178,119 units in August 2026, taking 8MCY26 volumes to 1.40mn units (+28% YoY). Honda led with an 86% share, followed by United at 11%.
- On a cumulative 8MCY26 basis, GAL led company growth with a 144% YoY rise to 2,960 units, GHNI grew 64% to 4,165 units, and HCAR rose 54% to 21,249 units, aided by lower rates and a favorable base.


Company-wise growth (8MCY26)



Source: PAMA, BMA Research


- We expect auto sales momentum to stay uneven over the near term, as illustrated by August's mixed category performance. The SBP kept its policy rate unchanged at 11.5% for a third consecutive meeting on September 14, 2026, with inflation still running above target amid elevated energy costs linked to the Middle East conflict. With further monetary easing unlikely in the near term, consumer purchasing power and financing affordability could remain constrained, capping the pace of demand recovery even as cumulative 8MCY26 volumes stay well above last year.
- Looking ahead, the newly approved Auto Policy 2026-31 will be key to the sector's trajectory. Hybrids are set to lose their special sales-tax concession, though import duties will still decline gradually over five years. Implementation remains contingent on IMF sign-off given the fiscal impact of EV/hybrid concessions.

Tractor Market Share (August 2026)




Source: PAMA, BMA Research

Trucks Market Share (August 2026)



Source: PAMA, BMA Research

Motorcycle Market Share (August 2026)




Source: PAMA, BMA Research

units	Aug-26	Aug-25	YoY	Jul-26	MoM	8MCY26	8MCY25	YoY
Categories								
Passenger Vehicles	13,717	10,057	36%	17,216	-20%	120,654	82,893	46%
SUVs/Pickups	1,730	3,993	-57%	2,602	-34%	32,711	28,739	14%
Trucks	802	596	35%	854	-6%	6,024	3,863	56%
Buses	73	70	4%	65	12%	662	611	8%
Tractors	1,052	996	6%	1,242	-15%	18,023	13,886	30%
Motorcycles	178,119	148,063	20%	173,373	3%	1,400,708	1,092,861	28%
Brands								
Indus Motors	4,029	3,400	19%	5,089	-21%	33,201	27,579	20%
Pak Suzuki	7,522	7,154	5%	10,120	-26%	72,662	51,691	41%
Honda Atlas	2,633	1,073	145%	2,640	0%	21,249	13,785	54%
Hyundai Nishat	742	1,212	-39%	710	5%	7,673	9,149	-16%
Millat Tractors	809	682	19%	828	-2%	11,999	10,030	20%
Hino Pak	43	38	13%	50	-14%	370	402	-8%
Sazgar Engineering	0	3,116	-100%	3,225	-100%	31,626	25,402	25%
Ghandhara Automobile	391	138	183%	468	-16%	2,960	1,211	144%
Ghandhara Industries	540	354	53%	424	27%	4,165	2,536	64%
Dewan Farooque Motors	75	61	23%	62	21%	430	420	2%
Notable Models								
Civic and City	2,553	699	265%	2,529	1%	19,334	12,052	60%
Corolla and Yaris	3,079	2,553	21%	4,283	-28%	26,473	20,550	29%
Cultus	296	497	-40%	392	-24%	3,120	2,511	24%
Swift	1,472	1,473	0%	2,018	-27%	13,622	7,549	80%
Alto	5,339	4,193	27%	7,217	-26%	50,490	33,392	51%
Fortuner/IMV	950	847	12%	806	18%	6,728	7,029	-4%
BR-V	80	374	-79%	111	-28%	1,915	1,733	11%
Haval	0	1,045	-100%	663	-100%	12,203	7,929	54%
Tucson	2	631	-100%	171	-99%	2,312	3,472	-33%
Honda Motorcycle	153,236	126,529	21%	150,063	2%	1,204,029	921,560	31%


Source: PAMA, BMA Research

Cumulative PV Trend




Source: PAMA, BMA Research

Cumulative SUV/Pickups Trend




Source: PAMA, BMA Research

Cumulative Buses Trend




Source: PAMA, BMA Research

Cumulative Trucks Trend




Source: PAMA, BMA Research

Cumulative Tractors Trend



Source: PAMA, BMA Research

Cumulative Motorcycle Trend



Source: PAMA, BMA Research

Disclaimer

This research report is for information purposes only and does not constitute nor is it intended as an offer or solicitation for the purchase or sale of securities or other financial instruments. Neither the information contained in this research report nor any future information made available with the subject matter contained herein will form the basis of any contract. Information and opinions contained herein have been compiled or arrived at by BMA Capital Management Limited from publicly available information and sources that BMA Capital Management Limited believed to be reliable. Whilst every care has been taken in preparing this research report, no research analyst, director, officer, employee, agent or adviser of any member of BMA Capital Management Limited gives or makes any representation, warranty or undertaking, whether express or implied, and accepts no responsibility or liability as to the reliability, accuracy or completeness of the information set out in this research report. Any responsibility or liability for any information contained herein is expressly disclaimed. All information contained herein is subject to change at any time without notice. No member of BMA Capital Management Limited has an obligation to update, modify or amend this research report or to otherwise notify a reader thereof in the event that any matter stated herein, or any opinion, projection, forecast or estimate set forth herein, changes or subsequently becomes inaccurate, or if research on the subject company is withdrawn. Furthermore, past performance is not indicative of future results.

The investments and strategies discussed herein may not be suitable for all investors or any particular class of investor. Investors should make their own investment decisions using their own independent advisors as they believe necessary and based upon their specific financial situations and investment objectives when investing. Investors should consult their independent advisors if they have any doubts as to the applicability to their business or investment objectives of the information and the strategies discussed herein. This research report is being furnished to certain persons as permitted by applicable law, and accordingly may not be reproduced or circulated to any other person without the prior written consent of a member of BMA Capital Management Limited. This research report may not be relied upon by any retail customers or person to whom this research report may not be provided by law. Unauthorized use or disclosure of this research report is strictly prohibited. Members of BMA Capital Management and/or their respective principals, directors, officers and employees may own, have positions or effect transactions in the securities or financial instruments referred herein or in the investments of any issuers discussed herein, may engage in securities transactions in a manner inconsistent with the research contained in this research report and with respect to securities or financial instruments covered by this research report, may sell to or buy from customers on a principal basis and may serve or act as director, placement agent, advisor or lender, or make a market in, or may have been a manager or a co-manager of the most recent public offering in respect of any investments or issuers of such securities or financial instruments referenced in this research report or may perform any other investment banking or other services for, or solicit investment banking or other business from any company mentioned in this research report. Investing in Pakistan involves a high degree of risk and many persons, physical and legal, may be restricted from dealing in the securities market of Pakistan. Investors should perform their own due diligence before investing. No part of the compensation of the authors of this research report was, is or will be directly or indirectly related to the specific recommendations or views contained in the research report. By accepting this research report, you agree to be bound by the foregoing limitations.

BMA Capital Management Limited and / or any of its affiliates, which operate outside Pakistan, do and seek to do business with the company(s) covered in this research document. Investors should consider this research report as only a single factor in making their investment decision. BMA Research Policy prohibits research personnel from disclosing a recommendation, investment rating, or investment thesis for review by an issuer/company prior to the publication of a research report containing such rating, recommendation or investment thesis.

Stock Rating

Investors should carefully read the definitions of all rating used within every research reports. In addition, research reports carry an analyst's independent view and investors should ensure careful reading of the entire research reports and not infer its contents from the rating ascribed by the analyst. Ratings should not be used or relied upon as investment advice. An investor's decision to buy, hold or sell a stock should depend on said individual's circumstances and other considerations. BMA Capital Limited uses a three tier rating system: i) Buy, ii) Neutral and iii) Underperform (new rating system effective Jan 1'18) with our rating being based on total stock returns versus BMA's index target return for the year. A table presenting BMA's rating definitions is given below:

Old rating system

Valuation Methodology

To arrive at our period end target prices, BMA Capital uses different valuation methodologies including

- Discounted cash flow (DCF, DDM)
- Relative Valuation (P/E, P/B, P/S etc.)
- Equity & Asset return based methodologies (EVA, Residual Income etc.)